In this article, we will take a look at the 10 Set-It-and-Forget-It Stocks to Buy Right Now.
A peace pact agreed upon by the United States and Iran on June 18 helped ease concerns about inflation that had been weighing on markets. The two sides declared a temporary agreement to maintain the ceasefire and reopen the Strait of Hormuz. The rebound occurred despite the Federal Reserve’s shift to a more hawkish stance, as inflation remained high and the labor market remained stable throughout the dispute with Iran.
Labor Department data on June 18 showed initial unemployment claims were a bit higher than expected but had cooled over the prior week. In contrast to their March estimates, nine Fed members now anticipate at least one rate hike before the year ends. Additionally, markets noted that Chair Kevin Warsh’s initial policy statement focused on achieving “price stability” but made no mention of maximum employment.
In response to Warsh’s remarks, SignatureFD Chief Investment Officer Tony Welch told Reuters that “markets got spooked by Warsh yesterday essentially promising to contain inflation.” That said, he added that the data remains supportive regardless of the Fed becoming increasingly hawkish.
Our Methodology
To identify the 10 set-it-and-forget-it stocks to buy, we screened for large-cap stocks (market cap above $10 billion) with a positive EPS over the past five years and an ROE of more than 15%. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. Deere & Company (NYSE:DE)
Deere & Company (NYSE:DE) ranks among the best set-it-and-forget-it stocks to buy right now. On May 26, RBC Capital increased its price target for Deere & Company (NYSE:DE) to $752 from $736, retaining an Outperform rating on the company’s shares. The firm referenced Deere’s second-quarter earnings, which outperformed forecasts despite the absence of an IEEPA tariff return.
Deere & Company (NYSE:DE) earned $6.55 per share, above the estimates of $5.70, while revenue came in at $13.37 billion, exceeding the expected $11.56 billion.
RBC highlighted that Deere’s fiscal 2026 outlook remained steady, given that the tariff return advantage was offset by a number of factors, including a downturn in South America. According to the firm, Deere continues to perform effectively in a hard climate.
Meanwhile, Freedom Broker increased its price target for Deere & Company (NYSE:DE) to $590 from $570 with a Hold rating. According to the firm, 2026 marks the low point of the major agricultural equipment cycle. Freedom also emphasized that Deere’s diverse portfolio is producing stronger intrinsic profitability at the cycle’s low stage when compared to past cycles.
Deere & Company (NYSE:DE) is an American company that manufactures agricultural, heavy, and forestry machinery, diesel engines, heavy-equipment drivetrains, and lawn-care equipment. The company also provides financial services and engages in other business operations.
9. Intuitive Surgical, Inc. (NASDAQ:ISRG)
Intuitive Surgical, Inc. (NASDAQ:ISRG) ranks among the best set-it-and-forget-it stocks to buy right now. On June 2, Piper Sandler restated its Overweight rating and $580 target on Intuitive Surgical, Inc. (NASDAQ:ISRG). The firm’s recent field check with the head of robotics at a prominent U.S. healthcare institution confirmed the firm’s positive opinion of the company. The hospital system has significant expertise with Intuitive Surgical’s da Vinci system, notably the DV5 model, as well as other robotic solutions.
The field check focused on issues regarding the long-term viability of US volume growth, third-party equipment reprocessing, and increasing competition.
Piper Sandler recognized many growth catalysts for Intuitive Surgical, Inc. (NASDAQ:ISRG), such as the ambulatory surgery center possibility, DV5 cardiovascular treatments, and My Intuitive+. The firm claimed it is convinced the basic fundamentals of the company remain solid and that prevailing concerns are blown out of proportion.
In addition, Intuitive Surgical, Inc. (NASDAQ:ISRG) recently announced upgrades to its da Vinci 5 robotic surgical system, which include improved Intuitive Telepresence and longer tool use, which is expected to be ready in June, subject to regulatory clearance.
Intuitive Surgical, Inc. (NASDAQ:ISRG) engages in the development, manufacturing, and marketing of da Vinci surgical systems and the Ion endoluminal system.
8. Stryker Corporation (NYSE:SYK)
Stryker Corporation (NYSE:SYK) ranks among the best set-it-and-forget-it stocks to buy right now. On June 5, Leerink reduced its price target for Stryker Corporation (NYSE:SYK) to $407 from $410 while keeping an Outperform rating on the company’s stock. The firm changed its SYK model in response to new 10-Q filings following the company’s first-quarter 2026 results.
The company fell short of analysts’ forecasts, reporting earnings per share of $2.60 vs an estimate of $2.98, with revenue of $6 billion coming below an expected $6.34 billion. Despite these challenges, Stryker Corporation (NYSE:SYK) has reiterated its 2026 projection.
The fiscal 2026 earnings per share projection fell by $0.01, reflecting management’s statement that a significant portion of the revenue deficit in the first quarter due to a cyberattack is expected to be recovered in the second half of the year. The firm’s EPS expectations for fiscal 2027 and fiscal 2028 were reduced by about 1% to reflect the impact of the most recent disclosures.
Leerink, however, stated that it still sees a solid risk/reward skew for Stryker Corporation (NYSE:SYK) and thinks the company is still among the better-positioned names in large-cap medical technology.
Founded in 1981, Stryker Corporation (NYSE:SYK) is a leading provider of medical technology products and services. Its business operations are divided into three primary divisions: Orthopedics, MedSurg, and Neurotechnology and Spine.
7. The TJX Companies, Inc. (NYSE:TJX)
The TJX Companies, Inc. (NYSE:TJX) ranks among the best set-it-and-forget-it stocks to buy right now. On June 9, UBS reaffirmed its Buy rating and $197 price target for The TJX Companies, Inc. (NYSE:TJX), citing data gathered from the 9th annual US Off-Price and Department Store Retailers Consumer Survey. According to the report, 71% of respondents believe T.J. Maxx provides excellent value for money in comparison to other department stores.
Based on the most recent poll wave, 78% of respondents cited T.J. Maxx’s wide assortment and products as an incentive to shop, a rise from 44% in Wave 8 and 37% in Wave 6. With 62% relevance, assortment breadth ranks as one of the most important decision-making factors.
Additionally, Truist Securities maintained a buy rating on The TJX Companies, Inc. (NYSE:TJX) on May 21 while increasing its price target from $175 to $190. The price target hike comes after TJX’s recent earnings report, which highlighted results that beat forecasts across a variety of metrics.
Instead of pointing to more general macroeconomic strength, Truist ascribed the outperformance to TJX’s competitive positioning and advantageous circumstances in the off-price retail industry.
The TJX Companies, Inc. (NYSE:TJX) is a well-known off-price clothing and home fashion retailer. Its store brands include T.J. Maxx, Marshalls, and HomeGoods, as well as international names such as T.K. Maxx and Winners.
6. Amgen Inc. (NASDAQ:AMGN)
Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy right now. On June 12, Piper Sandler reaffirmed its Overweight rating and $427 price target for Amgen Inc. (NASDAQ:AMGN). The firm published a detailed review of the Sjogren’s syndrome therapeutic development environment in advance of Amgen’s CD40 ligand-directed fusion protein dazodalibep’s Phase III conclusion in the latter half of 2026.
Amgen Inc. (NASDAQ:AMGN) is conducting research in two distinct Sjogren’s categories: moderate-to-severe symptoms-related burden with low systemic disease progression and moderate-to-severe systemic disease activity.
According to Piper Sandler, dazodalibep is a comparatively underappreciated part of Amgen’s growing immunology/inflammation pharmaceutical line.
In a similar vein, Morgan Stanley maintained its Overweight rating on Amgen Inc. (NASDAQ:AMGN) while increasing its price objective to $340 from $332 on June 9. The firm pointed out that Amgen’s portfolio of cutting-edge medications is bolstered by the company’s recent acquisition of Horizon.
According to Morgan Stanley, the stock’s future depends on pipeline development, with a major focus on MariTide against obesity.
Amgen Inc. (NASDAQ:AMGN) is a drug manufacturer that delivers human therapeutics through pharmaceutical wholesale distributors. The company was founded in 1980 and is headquartered in California.
While we acknowledge the potential of AMGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMGN and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Set-It-and-Forget-It Stocks to Buy Right Now.
Disclosure: None. Follow Insider Monkey on Google News.
